Table 3.

Comparison of change from baseline in MADRS total scores (ITT–LOCF)

Visit	Treatment group	n	Adjusted mean	SE	Difference vs placebo
					Mean	SE	95% CI
Week 1	Placebo	186	−3.4	0.38	–	–	–
	BUP150	190	−2.9	0.38	0.6	0.48	−0.4, 1.5
	BUP300	188	−2.7	0.38	0.7	0.49	−0.2, 1.7
Week 2	Placebo	186	−6.2	0.47	–	–	–
	BUP150	190	−5.0	0.47	1.2	0.61	0.0, 2.4
	BUP300	188	−5.0	0.47	1.2	0.61	−0.1, 2.4
Week 4	Placebo	186	−9.2	0.61	–	–	–
	BUP150	190	−8.3	0.60	0.9	0.78	−0.7, 2.4
	BUP300	188	−8.2	0.60	1.0	0.78	−0.6, 2.5
Week 6	Placebo	186	−11.8	0.70	–	–	–
	BUP150	190	−11.7	0.70	0.1	0.90	−1.7, 1.8
	BUP300	188	−11.1	0.69	0.7	0.90	−1.1, 2.4
Week 8	Placebo	186	−13.9	0.77	–	–	–
	BUP150	190	−14.4	0.77	−0.5	1.00	−2.4, 1.5
	BUP300	188	−12.9	0.76	1.0	1.00	−1.0, 3.0

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; SE, standard error; SR, sustained release; n, number; vs, versus.